The Canadian Find therapeutics (ten collaborators) has acquired an exclusive license to develop a new therapy for multiple sclerosis and other similar diseases thanks to SATT Conectus (Technology Transfer Acceleration Company) for an undisclosed amount. This therapeutic approach is the result of ten years of research carried out within the Institute of Medicine (University of Strasbourg), under the direction of Professor Dominique Bagnard. SATT Conectus funded the first preclinical pharmacology studies to the tune of 750,000 euros. The amounts of returns on investment are not disclosed. Within two years, Find therapeutics hopes to begin clinical studies. The company does not plan to market it for ten years. It was founded in 2020 by the Canadian venture capital funds CTI Life Sciences and adMare BioInnovations and two Strasbourg biotechs (Domain Therapeutics et Peptimimesis Pharma). The distribution of shares is not communicated.
